Handbook of Statistics in Clinical Oncology, Third Edition / Edition 3

Hardcover (Print)
Used and New from Other Sellers
Used and New from Other Sellers
from $108.74
Usually ships in 1-2 business days
(Save 13%)
Other sellers (Hardcover)
  • All (3) from $108.74   
  • New (2) from $108.74   
  • Used (1) from $156.38   


Many new challenges have arisen in the area of oncology clinical trials. New cancer therapies are often based on cytostatic or targeted agents, which pose new challenges in the design and analysis of all phases of trials. The literature on adaptive trial designs and early stopping has been exploding. Inclusion of high-dimensional data and imaging techniques have become common practice, and statistical methods on how to analyse such data have been refined in this area. A compilation of statistical topics relevant to these new advances in cancer research, this third edition of Handbook of Statistics in Clinical Oncology focuses on the design and analysis of oncology clinical trials and translational research.

Addressing the many challenges that have arisen since the publication of its predecessor, this third edition covers the newest developments involved in the design and analysis of cancer clinical trials, incorporating updates to all four parts:

  • Phase I trials: Updated recommendations regarding the standard 3 + 3 and continual reassessment approaches, along with new chapters on phase 0 trials and phase I trial design for targeted agents.
  • Phase II trials: Updates to current experience in single-arm and randomized phase II trial designs. New chapters include phase II designs with multiple strata and phase II/III designs.
  • Phase III trials: Many new chapters include interim analyses and early stopping considerations, phase III trial designs for targeted agents and for testing the ability of markers, adaptive trial designs, cure rate survival models, statistical methods of imaging, as well as a thorough review of software for the design and analysis of clinical trials.
  • Exploratory and high-dimensional data analyses: All chapters in this part have been thoroughly updated since the last edition. New chapters address methods for analyzing SNP data and for developing a score based on gene expression data. In addition, chapters on risk calculators and forensic bioinformatics have been added.

Accessible to statisticians and oncologists interested in clinical trial methodology, the book is a single-source collection of up-to-date statistical approaches to research in clinical oncology.

Read More Show Less

Editorial Reviews

From the Publisher
"A strength of the handbook is the large number of examples that are included in most chapters that expand on the theoretical basis underpinning the relevant methodology. Each chapter provides details of new developments in the specific methodology and provides a comprehensive list of references for the reader to seek further information when required. … The book contains a wealth of information about a wide range of statistical methodologies, some of which are not limited to clinical trials. … a valuable update to a resource that covers a comprehensive range of topics related to the design, analysis and interpretation of clinical trials in cancer research."
—Peter Baade, Australian & New Zealand Journal of Statistics, 2013

Praise for the Second Edition:
"The new topics and contributions in this edition include the recently developed tools for high-dimensional data and bioinformatics in clinical oncology research. A new section has been added emphasizing the importance and rapid developments of these topics over the 5 years since the publication of the first edition. Some of the original sections have been updated to include the state-of-the-art knowledge and tools in all topics. The end result is a comprehensive edited volume covering statistical and bioinformatics methods that provide the foundation for important research and clinical trials in cancer. … Like the last edition, this current edition will be an important addition to the libraries of all health research centers. The book will be prized as a reference book for biostatisticians, biomedical researchers, and oncologists for planning, conducting, analyzing, and interpreting cancer research."
Journal of the American Statistical Association, Vol. 104, No. 487, September 2009

"This is a expanded and revised second edition of a text that was initially well received by the community. The book comprised of 33 chapters, grouped into 6 sections. … The text is extremely well referenced. The authorship represents the leaders in the field. A significant strength of this book is its example-driven approach to the ‘out-of-the-box’ but practical issues faced by those conducting cancer clinical trials. The book provides a critical assessment of the state of science through a thorough review of the methods, applications, and available resources. … a detailed and mostly comprehensive text on the topics of cancer clinical trial design, conduct, analysis, and interpretation."
—Daniel Sargent, Sumithra Mandrekar, and Ann Oberg, Mayo Clinic, Biometrics, December 2006

Read More Show Less

Product Details

  • ISBN-13: 9781439862001
  • Publisher: Taylor & Francis
  • Publication date: 4/4/2012
  • Edition description: Revised
  • Edition number: 3
  • Pages: 657
  • Product dimensions: 6.40 (w) x 9.40 (h) x 1.60 (d)

Meet the Author

John J. Crowley is president and CEO of Cancer Research and Biostatistics (CRAB), Seattle, Washington, director of the SWOG Statistical Center, and a faculty member at the Fred Hutchinson Cancer Research Center. The author or coauthor of more than 350 refereed articles, book chapters, and other publications, Dr. Crowley is a fellow of the American Statistical Association and the American Association for the Advancement of Science and a member of the International Biometrics Society, the American Society for Clinical Oncology, and the International Association for the Study of Lung Cancer. He received his BA (1968) from Pomona College, Claremont, California, and his MS (1970) and PhD (1973) in biomathematics from the University of Washington, Seattle.

Antje Hoering, PhD, is a senior biostatistician at Cancer Research and Biostatistics (CRAB), Seattle, Washington. She is also an affiliate faculty member in the Department of Biostatistics at the University of Washington and an affiliate investigator at the Fred Hutchinson Cancer Research Center. Dr. Hoering is the lead statistician of the SWOG Myeloma Committee, the SWOG Early Therapeutics Subcommittee, and the Stand Up To Cancer, Pancreatic Dream Team. She is the coordinating statistician for the Myeloma Institute for Research and Therapy, the International Myeloma Committee, and the Pancreatic Cancer Research Team. She serves as a consultant on a variety of industry-sponsored studies and has been the biostatistics representative on two Type B meetings with the FDA. She is member of the American Statistical Association, the International Biometrics Society, and the International Myeloma Society. She received her BS (1985) from the University of Tubingen, Germany, her MS (1988) in physics from Oregon State University, Corvallis, and her PhD (1991) in physics from the Max Planck Institute for Theoretical Nuclear Physics, Heidelberg, Germany. She transitioned into biostatistics with a three-year NRSA postdoctoral fellowship with the Department of Biostatistics at the University of Washington and the Fred Hutchinson Cancer Research Center.

Read More Show Less

Table of Contents

Choosing a Phase I Design
Barry E. Storer
Dose Finding Designs Based on the Continual Reassessment Method
John O’Quigley and Alexia Iasonos
Pharmacokinetics in Clinical Oncology: Statistical Issues
Gary L. Rosner, Peter Müller, Simon Lunagomez, and Patrick A. Thompson
Statistics of Phase 0 Trials
Larry Rubinstein
CRM Trials for Assessing Toxicity and Efficacy
Sumithra Mandrekar and Dan Sargent
Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents
Antje Hoering, Michael LeBlanc, and John J. Crowley
Overview of Phase II Clinical Trials
Stephanie Green
Designs Based on Toxicity and Response
Gina R. Petroni and Mark R. Conway
Designs Using Time to Event Endpoints/Single Arm versus Randomized Phase II Designs
Catherine M. Tangen and John J. Crowley
Phase II Selection Designs
P.Y. Liu, James (Jim) Moon, and Michael LeBlanc
Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity
Michael LeBlanc, Cathryn Rankin, and John J. Crowley
Phase II/III Designs
Sally Hunsberger
On Use of Covariates in Randomization and Analysis of Clinical Trials
Garnet L. Anderson, Michael LeBlanc, P.Y. Liu, and John J. Crowley
Factorial Designs with Time to Event Endpoints
Stephanie Green
Early Stopping of Clinical Trials
Mary W. Redman
Noninferiority Trials
Kenneth J. Kopecky and Stephanie Green
Phase III Trials for Targeted Agents
Antje Hoering, Michael LeBlanc, and John J. Crowley
Adaptive Trial Designs
Brian P. Hobbs and J. Jack Lee
Design of a Clinical Trial for Testing the Ability of a Continuous Marker to Predict Therapy Benefit
William E. Barlow
Software for Design and Analysis of Clinical Trials
J. Jack Lee and Nan Chen
Cure-Rate Survival Models in Clinical Trials
Megan Othus, John J. Crowley, and Bart Barlogie
Design and Analysis of Quality of Life Data
Andrea B. Troxel and Carol M. Moinpour
Economic Analyses alongside Cancer Clinical Trials
Dean A. Regier and Scott D. Ramsey
Structural and Molecular Imaging in Cancer Therapy Clinical Trials
Brenda Kurland and David A. Mankoff
Prognostic Factor Studies
Martin Schumacher, Norbert Holländer, Guido Schwarzer, Harald Binder, and Willi Sauerbrei
Predictive Modeling of Gene Expression Data
Alexander Hapfelmeier, Waheed Babatunde Yahya, Robert Rosenberg, and Kurt Ulm
Explained Variation and Explained Randomness for Proportional Hazards Models
John O’Quigley and Ronghui Xu
Prognostic Groups by Tree-Based Partitioning and Data Refinement Methods
Michael LeBlanc and John J. Crowley
Risk Calculators
Donna Pauler Ankerst and Yuanyuan Liang
Developing a Score Based upon Gene Expression Profiling and Validation
Pingping Qu, John Shaughnessy, Bart Barlogie, and John J. Crowley
Analysis of DNA Microarrays
Shigeyuki Matsui and Hisashi Noma
Methods for SNP Regression Analysis in Clinical Studies:Selection, Shrinkage, and Logic
Michael LeBlanc, Bryan Goldman, and Charles Kooperberg
Forensic Bioinformatics
Keith A. Baggerly and Kevin R. Coombes

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)